NAMS Stock — NewAmsterdam Pharma Company N.V.: Cash, EV, Pipeline

Share price

$22.49

Market cap

$2,688.4M

Cash

$633.9M

Enterprise value

$2,054.5M

Balance sheet

Cash	$633.9M
Debt	$0.0M
Net cash	$633.9M
Enterprise value	$2,054.5M
Basic shares	117.7M shares
Fully diluted shares	151.1M shares
Fully diluted market cap	$3,399.3M
Cash per share	$5.39

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NAMS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Oct 13 - Nov 24	Obicetrapib 10mg	Phase 2	Antioxidant Absorption	—
Dec 13, 2026 - Jan 24, 2027	Obicetrapib	Phase 3	Atherosclerotic Cardiovascular Disease	Q1 2027
Dec 13, 2026 - Jan 24, 2027	obicetrapib 10 mg	Phase 2	Dyslipidemias	—
Dec 13, 2027 - Jan 24, 2028	obicetrapib 10 mg	Phase 3	Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic	Q1 2027
Apr 12 - May 24	obicetrapib 10 mg	Phase 3	Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)	Q1 2027
Oct 13 - Nov 24	Obicetrapib 10 mg	Phase 2	Preclinical Alzheimer's Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Obicetrapib

Phase 3 · Active Modality: oral CETP inhibitor

Target CETP

Partnerships Menarini (exclusive commercialization rights in the majority of European countries)

Indications

LDL-C lowering in ASCVD and HeFH (Phase 3)
primary hypercholesterolemia (HeFH and non-familial/mixed dyslipidemia) (Phase 3)

Catalysts

— Q4 2026
— Q1 2027
— end of 2027
— 2H 2026

Status note BROADWAY, BROOKLYN and TANDEM Phase 3 completed; CHMP positive opinion July 2026; potential Germany/UK launch Q4 2026. One row covers monotherapy and ezetimibe fixed-dose combination.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Obicetrapib
Lead indication	Atherosclerotic Cardiovascular Disease
Lead phase	Phase 3
Active trials	7
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05202509	Phase 3	Active, not recruiting	Sponsor	NAMS	—	Atherosclerotic Cardiovascular Disease	Q1 2027
NCT06305559	Phase 3	Active, not recruiting	Sponsor	NAMS	—	Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic	Q1 2027
NCT07219602	Phase 3	Active, not recruiting	Sponsor	NAMS	—	Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)	Q1 2027
NCT06496243	Phase 2	Recruiting	Sponsor	NAMS	—	Dyslipidemias	—
NCT07794670	Phase 2	Not yet recruiting	Sponsor	NAMS	—	Preclinical Alzheimer's Disease	—
NCT06982508	Phase 2	Recruiting	Sponsor	NAMS	—	Antioxidant Absorption	—
NCT05972278	Phase 1	Active, not recruiting	Sponsor	NAMS	—	Lipid Metabolism	—
NCT07478887	Not disclosed	Recruiting	Collaborator	Johns Hopkins University	AMGN	Cardiovascular Risk; LDL-C; Lipids	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 8 active trials for NewAmsterdam Pharma on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	18,589,235	+1,145,128	13.58%	2026-08-14
ADAR1 Capital Management	118,623	no change	0.19%	2026-08-14
Logos Global Management	0	-600,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NAMS — NewAmsterdam Pharma Company N.V.